Effect of intravenous immunoglobulins to postpone the gestational age of first intrauterine transfusion in very severe red blood cell alloimmunization: A case-control study.


Journal

Journal of gynecology obstetrics and human reproduction
ISSN: 2468-7847
Titre abrégé: J Gynecol Obstet Hum Reprod
Pays: France
ID NLM: 101701588

Informations de publication

Date de publication:
Sep 2021
Historique:
received: 15 12 2020
revised: 03 03 2021
accepted: 10 03 2021
pubmed: 21 3 2021
medline: 24 12 2021
entrez: 20 3 2021
Statut: ppublish

Résumé

Early intrauterine transfusion (IUT) is associated with a higher risk of fetal loss. Our objective was to evaluate the efficiciency of intravenous immunoglobulins (IVIG) to postpone the gestational age at first IUT beyond 20 weeks of gestation (WG) compared to the previous pregnancy in case of very severe red blood cell (RBC) alloimmunization. Very severe RBC alloimmunization was defined by a high titer of antibodies and a previous pregnancy complicated by a first IUT before 24 WG and/or perinatal death directly related to alloimmunization. We performed a single-center case-control study. Cases and controls were patients respectively treated with weekly IVIG infusions started before 13 WG, and without. Twenty cases and 21 controls were included. Gestational age (GA) at first IUT was postponed after 20 WG in 18/20 (90 %) of patients treated with IVIG and in 15/21 (71 %) in the control group (p = 0.24). Compared to the previous pregnancy, the GA at first IUT was postponed by a median of 22 [+11; +49] days in the IVIG group and occurred in average 2 days earlier [-17 ; +12] in the non-treated group (p = 0.02). There was no difference between number of IUT and need for exchange-transfusion. IVIG treatment was associated with a significant decrease of antibodies' quantitation. In our series, IVIG tends to differ first IUT beyond 20 WG and have a significant effect in postponing the gestational age of the first IUT in patients with very severe RBC alloimmunization.

Sections du résumé

BACKGROUND BACKGROUND
Early intrauterine transfusion (IUT) is associated with a higher risk of fetal loss. Our objective was to evaluate the efficiciency of intravenous immunoglobulins (IVIG) to postpone the gestational age at first IUT beyond 20 weeks of gestation (WG) compared to the previous pregnancy in case of very severe red blood cell (RBC) alloimmunization.
STUDY DESIGN AND METHODS METHODS
Very severe RBC alloimmunization was defined by a high titer of antibodies and a previous pregnancy complicated by a first IUT before 24 WG and/or perinatal death directly related to alloimmunization. We performed a single-center case-control study. Cases and controls were patients respectively treated with weekly IVIG infusions started before 13 WG, and without.
RESULTS RESULTS
Twenty cases and 21 controls were included. Gestational age (GA) at first IUT was postponed after 20 WG in 18/20 (90 %) of patients treated with IVIG and in 15/21 (71 %) in the control group (p = 0.24). Compared to the previous pregnancy, the GA at first IUT was postponed by a median of 22 [+11; +49] days in the IVIG group and occurred in average 2 days earlier [-17 ; +12] in the non-treated group (p = 0.02). There was no difference between number of IUT and need for exchange-transfusion. IVIG treatment was associated with a significant decrease of antibodies' quantitation.
CONCLUSION CONCLUSIONS
In our series, IVIG tends to differ first IUT beyond 20 WG and have a significant effect in postponing the gestational age of the first IUT in patients with very severe RBC alloimmunization.

Identifiants

pubmed: 33741541
pii: S2468-7847(21)00061-1
doi: 10.1016/j.jogoh.2021.102119
pii:
doi:

Substances chimiques

Immunoglobulins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102119

Informations de copyright

Copyright © 2021 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors report no declarations of interest.

Auteurs

Emeline Maisonneuve (E)

Fetal Medicine Department, Armand-Trousseau Hospital, 26, Avenue du Dr Arnold Netter, 75012, Paris, France; Clinical Unit of CNRHP: Centre National de Référence en Hémobiologie Périnatale, Armand-Trousseau Hospital, 26, Avenue du Dr Arnold Netter, 75012, Paris, France. Electronic address: emelinem@yahoo.com.

Anaïs Dugas (A)

Fetal Medicine Department, Armand-Trousseau Hospital, 26, Avenue du Dr Arnold Netter, 75012, Paris, France.

Stéphanie Friszer (S)

Fetal Medicine Department, Armand-Trousseau Hospital, 26, Avenue du Dr Arnold Netter, 75012, Paris, France; Clinical Unit of CNRHP: Centre National de Référence en Hémobiologie Périnatale, Armand-Trousseau Hospital, 26, Avenue du Dr Arnold Netter, 75012, Paris, France.

Cécile Toly-Ndour (C)

Biological Unit of CNRHP: Centre National de Référence en Hémobiologie Périnatale, Saint-Antoine Hospital, 184 rue du Faubourg Saint-Antoine, Paris, France.

Laura Cariot (L)

Fetal Medicine Department, Armand-Trousseau Hospital, 26, Avenue du Dr Arnold Netter, 75012, Paris, France.

Ferdinand Dhombres (F)

Fetal Medicine Department, Armand-Trousseau Hospital, 26, Avenue du Dr Arnold Netter, 75012, Paris, France; Sorbonne Université, Paris, France.

Anne Cortey (A)

Fetal Medicine Department, Armand-Trousseau Hospital, 26, Avenue du Dr Arnold Netter, 75012, Paris, France; Clinical Unit of CNRHP: Centre National de Référence en Hémobiologie Périnatale, Armand-Trousseau Hospital, 26, Avenue du Dr Arnold Netter, 75012, Paris, France.

Agnès Mailloux (A)

Biological Unit of CNRHP: Centre National de Référence en Hémobiologie Périnatale, Saint-Antoine Hospital, 184 rue du Faubourg Saint-Antoine, Paris, France.

Bruno Carbonne (B)

Obstetrics and Gynecology Department, Princesse Grace Hospital, 1, Avenue Pasteur, 98000, Monaco.

Jean-Marie Jouannic (JM)

Fetal Medicine Department, Armand-Trousseau Hospital, 26, Avenue du Dr Arnold Netter, 75012, Paris, France; Clinical Unit of CNRHP: Centre National de Référence en Hémobiologie Périnatale, Armand-Trousseau Hospital, 26, Avenue du Dr Arnold Netter, 75012, Paris, France; Sorbonne Université, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH